Sector News

Is Pozen prepping to sell out? Sudden CEO exit, new Irish subsidiary hint yes

June 2, 2015
Life sciences
Pozen has had its share of woes in recent months: Manufacturing problems at its contract supplier tanked new drug applications twice in a row, and Big Pharma partner Sanofi bailed on their development deal for the new-and-improved aspirins.
 
Now, its founder, chairman and CEO is taking a hike. And Pozen’s choice of a replacement hints that a sale may be on the way.
 
John Plachetka–described as an outspoken, even “fiery” type–is retiring from his CEO post, effective immediately. He’s also exiting the board of directors completely. To replace him as CEO, Pozen has brought on Adrian Adams, CEO at Auxilium till it was sold off to Endo in January. Board member Arthur Kirsch will take over as chairman, and one of Adams’ Auxilium colleagues, Andrew Koven, joined as president.
 
Pozen revealed those moves Monday. By this morning, the North Carolina-based drugmaker was announcing that it had set up an Irish subsidiary, Pozen Limited, as a springboard for international growth, WRAL TechWire points out. 
 
Or perhaps an eventual tax inversion? Ireland is a tax-friendly jurisdiction that now hosts several major drug companies, including Actavis, Perrigo and Shire. Also, to recruit Adams and Koven, Pozen gave each a stake in the company–5.4% and 4.1%, respectively. The shares vest over four years; though we haven’t seen their agreements with Pozen, standard exec contracts allow for accelerated vesting in a sale.
 
Other evidence that Pozen may be grooming itself for potential bidders is Adams’ employment history, TechWire notes; it’s a litany of top-executive posts at companies that sold to larger drugmakers. Kos Pharmaceuticals (bought by Abbott Labs), Sepracor (bought by Dainippon), and Inspire Pharmaceuticals (bought by Merck), and of course Auxilium. Inspire, we should also mention, was founded by none other than Plachetka himself.
 
“This experience will be critical in helping Pozen in assessing our strategic options at this time,” the company said in a statement about the management switch, “and leading [pain reliever] Yosprala through the final anticipated stages of approval and into commercial launch.” 
 
Yosprala is the aspirin project Sanofi abandoned. Combining aspirin with the stomach drug omeprazole, the pair of treatments is designed to help patients take daily aspirin to prevent heart attacks, strokes, and other CV complications. The FDA rejected the meds for the second time in December, citing problems at an API supplier. 
 
By Tracy Staton
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend